NASDAQ · Medical - Pharmaceuticals

Cellyan Biotechnology Co., Ltd (HKPD) Stock

$0.11 +11.11% NASDAQ: HKPD Healthcare

Valuation

MetricValue
Price$0.11
Market Cap$1.23M
P/E Ratio-4.75
P/B Ratio0.39
P/S Ratio0.08
EPS (TTM)$0.00
52-Week High$1.72
52-Week Low$0.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-15.43%
ROA-8.84%
ROCE-10.31%
Gross Margin11.89%
Operating Margin0.65%
Net Margin-8.46%
Debt/Equity0.13
Current Ratio3.00

Annual Financials (USD)

Metric2023202420252026
Revenue$13.0M$17.0M$20.0M$13.0M
Operating Profit$1.0M$2.0M$0$-1.0M
Net Profit$1.0M$1.0M$0$-1.0M
EPS$0.09$0.18$0.00$-0.05
Op Margin8.3%9.6%0.7%-7.4%

Balance Sheet (USD)

Metric2023202420252026
Total Assets$3.0M$9.0M$9.0M$13.0M
Total Liabilities$3.0M$4.0M$4.0M$3.0M
Cash$1.0M$1.0M$1.0M$0
Borrowings$1.0M$2.0M$2.0M$1.0M

Latest News

Top Premarket Decliners MT Newswires · Jul 17, 2026 Cellyan Biotechnology Gets 180-Day Nasdaq Grace Period on Bid-Price Rule MT Newswires · Jul 16, 2026 Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period GlobeNewswire · Jul 16, 2026 Cellyan Biotechnology Files $200 Million Mixed Shelf MT Newswires · Jun 12, 2026

Cash Flow (USD)

Metric2023202420252026
Operating Cash Flow$2.0M$0$1.0M$-1.0M
Investing Cash Flow$0$0$-3.0M$1.0M
Financing Cash Flow$0$0$-1.0M$0
Net Cash Flow$0$0$0$-1.0M
Free Cash Flow$2.0M$0$0$-1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-2.37
FCF Yield-69.20%
Quick Ratio3.75
Interest Coverage-7.46
Return 1Y-66.62%
Return 3Y—
Return 5Y—

Ownership

Insiders Held33.13%
Institutions Held0.32%
Institutions Float Held0.47%
Institutional HolderSharesReport Date
Stonex Group Inc.39,3952026-03-31
Clear Street Group Inc.12,0192026-03-31
Two Sigma Investments, LP10,8322026-03-31
UBS Group AG1102026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd is led by CEO Chenyu Liang, employs 27 people, headquartered in HK, publicly traded since 2025.

Cellyan Biotechnology Co., Ltd (HKPD) stock trades at $0.11 with a market capitalization of $1.23M. The stock is valued at a price-to-earnings (P/E) ratio of -4.75, price-to-book of 0.39, price-to-sales of 0.08. Over the past 52 weeks the stock has ranged between $0.10 and $1.72, and currently trades 93.6% below its 52-week high.

On profitability, Cellyan Biotechnology Co., Ltd generates a return on equity (ROE) of -15.43%, return on capital employed of -10.31%, an operating margin of 0.65%, a net profit margin of -8.46%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides